Acceleron to Participate in Three Upcoming Healthcare Investor Conferences
04 September 2018 - 9:00PM
Business Wire
Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical
company in the discovery and development of TGF-beta therapeutics
to treat serious and rare diseases, today announced that senior
management will participate in three upcoming healthcare investor
conferences.
Conference
Details:
Event: Citi’s 13th Annual Biotech ConferenceDate:
Wednesday, September 5, 2018Location: Boston, MA
Event: Morgan Stanley 16th Annual Global Healthcare
ConferenceDate/Time: Thursday, September 13, 2018 at 1:30
p.m. EDTLocation: New York, NY
Event: Leerink Partners Roundtable Series: Rare Disease &
OncologyDate/Time: Tuesday, October 2, 2018 at 9:30 a.m.
EDTLocation: New York, NY
A live webcast of the fireside chat at the Morgan Stanley and
Leerink Partners conferences may be accessed on the Investors/Media
page of the Company's website at www.acceleronpharma.com. A
replay of each webcast will be available approximately two hours
after the event on the Acceleron website.
About Acceleron
Acceleron is a Cambridge-based, clinical-stage
biopharmaceutical company dedicated to the discovery, development,
and commercialization of therapeutics to treat serious and rare
diseases. The Company's leadership in the understanding of TGF-beta
biology and protein engineering generates innovative compounds that
engage the body's ability to regulate cellular growth and
repair.
Acceleron focuses its research and development efforts in
hematologic, neuromuscular, and pulmonary diseases. In hematology,
the Company and its global collaboration partner, Celgene, are
developing luspatercept for the treatment of chronic anemia in
myelodysplastic syndromes, beta-thalassemia, and myelofibrosis.
Acceleron is also advancing its neuromuscular franchise with two
distinct Myostatin+ agents, ACE-083 and ACE-2494, and a Phase 2
pulmonary program with sotatercept in pulmonary arterial
hypertension.
For more information, please visit www.acceleronpharma.com.
Follow Acceleron on Social
Media: @AcceleronPharma and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180904005257/en/
Acceleron Pharma Inc.Todd James, IRC, 617-649-9393Vice
President, Investor Relations and Corporate CommunicationsorCandice
Ellis, 617-649-9226Manager, Investor Relations and Corporate
CommunicationsorMedia:Matt Fearer, 617-301-9557Director, Corporate
Communications
Acceleron Pharma (NASDAQ:XLRN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acceleron Pharma (NASDAQ:XLRN)
Historical Stock Chart
From Apr 2023 to Apr 2024